Our unique in vitro bone cell assays, including osteoclast assays for antiresorptive compounds and osteoblast assays for anabolic compounds are perfect tools for selecting most potent drug candidates for further testing in animal models. While these assays are specifically designed for testing osteoporosis drug compounds, they are also extremely useful for testing new cancer drug compounds, especially if the compounds are targeting bone cells or bone cell interactions.
These in vitro services are complimented by our wide selection of in vivo models for osteoporosis as well as cancer and osteoarthritis.
The osteoporosis animal models currently available in Pharmatest include rat ovariectomy (OVX), orchidectomy (ORX) and immobilization models and an intact mouse model of glucocorticoid-induced osteoporosis (GIO). Of these, especially the rat OVX model is of great significance because FDA requires in their guidelines that any therapeutic agent for postmenopausal osteoporosis must be tested in this model to obtain FDA approval. Therefore, our osteoporosis animal models (OVX/ORX) can be performed according to FDA/EMEA guidelines, allowing the use of the results in drug approval process.
Ovariectomized rats develop osteoporosis rapidly after the operation due to estrogen withdrawal, and the model resembles postmenopausal osteoporosis. The ORX model is a corresponding model for males, where osteoporosis is caused by testosterone withdrawal. Immobilization causes osteoporosis to rats with a different mechanism, due to decreased bone formation, and the rat immobilization model is a useful additional test model especially for anabolic compounds. Furthermore, the use of glucocorticoids causes osteoporosis with a unique mechanism affecting primarily bone formation. The GIO model can be used either to test the effects of new glucocorticoids on bone or to test the effects of new test compounds on glucocorticoid-induced osteoporosis.
In addition to these osteoporosis animal models, we offer animal models of cancer bone metastasis and osteoarthritis. Our breast cancer bone metastasis model is a highly specialized and clinically relevant model of cancer dissemination, which closely resembles the clinical situation. This model is an extremely useful tool for preclinical cancer drug development. Pharmatest's in vivo rabbit osteoarthritis model can be used to test the efficacy of a drug compound efficacy in the treatment of osteoarthritis.
Finally, we also provide stand-alone bone analysis services, including BMD measurements, histology, static and dynamic histomorphometry, ash weight analysis, mechanical testing and biochemical markers of bone metabolism.
Pharmatest Services can help drug discovery and development companies accelerate their proof-of-concept, as well as lead selection and validation processes. This will increase profitability while reducing fixed costs and financial risks. We would be happy to work together with you to find the best way to accelerate your drug discovery pipeline.